Cipla gets USFDA's approval for Isoproterenol Hydrochloride Injection

14 Jun 2018 Evaluate

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-use sterile Ampoule from the United States Food and Drug Administration (US FDA). The company's Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is APrated generic therapeutic equivalent version of Hospira Inc’s Isuprel Injection, 0.2mg/ml.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1434.60 -13.00 (-0.90%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×